GlassScriptPhysician profile
Denise A Johnson
NPI 1265416580
$7,159.56
in general payments reported to CMS, 2019-2025
30 companies · $790 in 2025
The $790 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $472 · 2021: $963 · 2022: $2,621 · 2023: $942 · 2024: $1,081 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,813.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,863.10 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $614.43 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $585.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $464.24 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $453.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $312.31 | 2023-2025 | |
| Exact Sciences Corporation | $189.60 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $174.53 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $164.28 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $131.01 | 2019-2023 | Belsomra, Steglatro |
| Amgen INC. | $125.74 | 2021-2025 | Repatha, Otezla, Otezla |
| Idorsia Pharmaceuticals US INC | $115.48 | 2022-2024 | Quviviq |
| Stryker Corporation | $112.16 | 2019 | |
| Dexcom, INC. | $102.45 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.22 | 2021-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $90.04 | 2020-2023 | |
| Biohaven Pharmaceuticals, INC. | $84.62 | 2021 | |
| Abbott Laboratories | $84.31 | 2021-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $76.91 | 2022 | |
| Abiomed | $60.19 | 2024 | Impella |
| Adlon Therapeutics L.P. | $42.67 | 2021 | |
| Coloplast Corp | $42.15 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $29.63 | 2025 | Neffy |
| Kowa Pharmaceuticals America, INC. | $29.48 | 2025 | Zoryve |
| Bausch Health US, LLC | $24.12 | 2019 | |
| Sanofi Pasteur INC. | $23.42 | 2025 | |
| Paratek Pharmaceuticals, INC. | $20.96 | 2021 | |
| Dynavax Technologies Corporation | $19.75 | 2024 | Heplisav-B |
| Genentech USA, INC. | $18.63 | 2019 | |
| Eisai INC. | $13.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.